About this article
Article Category: Research Article
Published Online: Apr 22, 2021
Page range: 9 - 16
Received: Nov 21, 2020
Accepted: Dec 11, 2020
DOI: https://doi.org/10.2478/fco-2019-0023
Keywords
© 2020 Amrallah A. Mohammed, Hani EL-Tanni, Hani M. EL-Khatib, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Clinical trials in advanced desmoids tumors/Aggressive fibromatosis (DTs/AF).
| NCT ID | Trial description | Intervention | Trial phase | Last updated | Estimated Study Completion Date |
|---|---|---|---|---|---|
| To determine the response rate of PF-03084014 in patients with DT/AF progressed after receiving at least one line of standard treatment. | PF-03084014; small-molecule Gamma- secretase inhibitor | Phase 2 | October 6, 2015 | December 2016 | |
| To define the activity of imatinib in the treatment local treatment of DT/AF, and progression to determine after the molecular basis for response. | Imatinib | Phase 2 | July 10, 2015 | December 2016 | |
| To compares the effects of sorafenib in patients with previously treated DT/AF. | -Sorafenib -Laboratory Biomarker Analysis* - Quality-of-Life Assessment - Placebo | Phase 3 | December 22, 2015 | March 2016 | |
| To evaluate the activity and safety of imatinib in patients with DTs/AF who, after receiving the standard therapy | Imatinib | Phase 2 | December 1, 2015 | June 2016 | |
| To evaluate mTOR inhibitor, clinical and histological studies following a course of pre-operative Sirolimus. | Sirolimus | Phase 1 Phase 2 | Last updated: September 22, 2015 | March 2017 | |
| To evaluate efficacy and safety of protocol pazopanib combining versus a methotrexate chemotherapy and vinblastine in progressive DTs. | Drug: pazopanib treatment Drug: Active Comparator: Vinblastine and Methotrexate | Phase 2 | November 25, 2015 | July 2019 | |
| To test the safety and effectiveness of hormone daily endoxifen receptor in positive individuals DTs with after first line. | Z-Endoxifen | Phase 1 | July 30, 2015 | October 2016 | |
| To determine the lowest dose of erythromycin that can inhibit growth of in DT/AF. | Erythromycin | Phase 4 | January 29, 2015 | December 2017 | |
| To determine the safety of OMP-54F28 in subjects with previously treated DT/AF. | OMP-54F28 | Phase 1 | April 13, 2015 | July 2016 |